Management of Thyroid Nodules by Bethesda Category
Each Bethesda category carries a specific malignancy risk that directly determines whether surveillance, repeat biopsy, molecular testing, or surgery is indicated. 1
Bethesda I: Nondiagnostic/Unsatisfactory
Repeat ultrasound-guided FNA is mandatory for nondiagnostic samples, which occur in 5-20% of cases. 1
- Perform repeat FNA under ultrasound guidance to ensure adequate sampling from the most suspicious area of the nodule 1
- If the second FNA remains nondiagnostic, assess the number of suspicious ultrasound features present 1
- Consider core needle biopsy (CNB) if repeat FNA is still inadequate, as CNB provides superior diagnostic accuracy and correct histological grading 1
- For nodules with multiple high-risk ultrasound features (microcalcifications, irregular margins, marked hypoechogenicity) despite nondiagnostic cytology, proceed to surgical consultation rather than continued observation 1
Bethesda II: Benign
Surveillance with ultrasound is the standard of care for Bethesda II nodules, as the malignancy risk is only 1-3%. 1
Surveillance Protocol
- Perform initial follow-up ultrasound at 12-24 months to assess for interval growth or development of suspicious features 2, 1
- If the nodule remains stable, continue surveillance at 12-24 month intervals 2
- Monitor for compressive symptoms including dysphagia, dyspnea, or voice changes 1
Indications for Surgery Despite Benign Cytology
- Compressive symptoms clearly attributable to the nodule 1
- Significant cosmetic concerns that are patient-driven 1
- Large nodules >4 cm due to increased false-negative rate (up to 11-33%) and higher risk of compressive symptoms 1
- Development of suspicious features on follow-up ultrasound despite initially benign cytology 1
Critical Pitfall
- A reassuring FNA should not override worrisome clinical findings, as false-negative results occur in up to 11-33% of cases 1
- Documented growth of ≥3 mm in any dimension during surveillance mandates repeat FNA regardless of prior benign cytology 1
Bethesda III: Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)
Molecular diagnostic testing (BRAF V600E, RET/PTC, RAS, PAX8/PPARγ) or gene expression classifiers should be used to guide management decisions for AUS/FLUS nodules. 1
Management Algorithm
- Order molecular testing for BRAF, RAS, RET/PTC, and PAX8/PPARγ mutations, as 97% of mutation-positive nodules are malignant 1
- If molecular testing is positive for high-risk mutations, proceed directly to diagnostic lobectomy 1
- If molecular testing is negative or unavailable, repeat ultrasound-guided FNA is recommended 1
- Consider core needle biopsy if repeat FNA remains indeterminate 1
Updated Risk Stratification
- The 2023 Bethesda System simplifies AUS subcategorization into 2 subgroups based on implied malignancy risk and molecular profiling 3
- AUS has a well-balanced sensitivity and specificity, functioning as a screening rather than diagnostic category 4
- The risk of neoplasia/risk of malignancy (RON/ROM) ratio is significantly higher in AUS (1.56) compared to follicular neoplasm (1.03), supporting conservative management 4
Bethesda IV: Follicular Neoplasm / Suspicious for Follicular Neoplasm
Surgery is required for definitive diagnosis of Bethesda IV nodules, as FNA cannot distinguish follicular adenoma from follicular carcinoma. 1
Diagnostic Approach
- Measure serum calcitonin to screen for medullary thyroid cancer, which has higher sensitivity than FNA alone 1
- Perform molecular testing for BRAF, RAS, RET/PTC, and PAX8/PPARγ mutations to refine malignancy risk 1
- If TSH is normal and thyroid scan shows "cold" appearance, proceed to surgery for definitive diagnosis 1
Surgical Planning
- Diagnostic lobectomy is the initial surgical approach for unifocal disease 1
- Total or near-total thyroidectomy is recommended if molecular testing is positive for high-risk mutations or if the nodule is ≥1 cm with confirmed malignancy on final histology 1
- Pre-operative neck ultrasound should assess cervical lymph node status 1
- The malignancy rate for follicular neoplasms ranges from 12-34% depending on subcategory 2
Bethesda V: Suspicious for Malignancy
Immediate referral to an endocrine surgeon for total or near-total thyroidectomy is recommended for Bethesda V nodules. 1
Management Protocol
- Arrange surgical consultation within 2-4 weeks of the pathology report to minimize treatment delays 1
- Perform pre-operative neck ultrasound to systematically assess both central and lateral cervical lymph node basins for suspicious characteristics 1
- Total or near-total thyroidectomy is recommended for nodules ≥1 cm 1
- Compartment-oriented lymph node dissection is indicated when lymph node metastases are suspected preoperatively or proven intraoperatively 1
Post-Surgical Management
- Surgery is typically followed by radioactive iodine (¹³¹I) ablation to eliminate remnant thyroid tissue and potential microscopic residual tumor, which decreases recurrence risk 1
Bethesda VI: Malignant
Immediate referral for total or near-total thyroidectomy with pre-operative assessment of lymph node compartments is mandatory for Bethesda VI nodules. 1
Surgical Approach
- Total or near-total thyroidectomy is recommended for nodules ≥1 cm with confirmed malignancy, multifocal disease, or familial thyroid cancer 1
- Less extensive surgery (lobectomy) may be acceptable for unifocal disease <1 cm, intrathyroidal, with favorable histology (classical papillary or minimally invasive follicular) diagnosed at final histology 1
- Pre-operative neck ultrasound must assess cervical lymph node status in both central and lateral compartments 1
- Compartment-oriented lymph node dissection should be performed when lymph node metastases are suspected or proven 1
Special Considerations
- Microcalcifications on ultrasound are highly specific for papillary thyroid carcinoma 1
- Measure serum calcitonin preoperatively to screen for medullary thyroid cancer 1
- Molecular testing for BRAF, RAS, RET/PTC, and PAX8/PPARγ mutations can provide prognostic information 1
Updated Malignancy Risks (2023 Bethesda System)
The 2023 revision provides updated risk of malignancy (ROM) for each category, accounting for the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) as non-malignant 3, 5:
- Bethesda I (Nondiagnostic): 5-10% ROM 3
- Bethesda II (Benign): 0-3% ROM 3, 5
- Bethesda III (AUS/FLUS): 6-18% ROM 3
- Bethesda IV (Follicular Neoplasm): 10-40% ROM 3
- Bethesda V (Suspicious for Malignancy): 45-60% ROM 3
- Bethesda VI (Malignant): 94-96% ROM 3
Special Considerations for Subcentimeter Nodules
For nodules <1 cm classified as high-risk by ultrasound (TI-RADS 4 or 5), FNA is not routinely recommended unless high-risk clinical factors are present. 2, 6
High-Risk Clinical Factors That Lower FNA Threshold
- History of head and neck irradiation (increases malignancy risk approximately 7-fold) 2
- Family history of thyroid cancer, particularly medullary carcinoma or familial syndromes 2
- Suspicious cervical lymphadenopathy 2
- Subcapsular location of the nodule 2, 6
- Age <15 years or male gender 2
- Rapidly growing nodule 2
Management Without FNA
- Active surveillance is considered safe for subcentimeter high-risk nodules, with low progression rates manageable through regular imaging follow-up 1
- Perform ultrasound surveillance at 6-12 months to assess for growth or development of more suspicious features 6
Common Pitfalls to Avoid
- Never rely on TSH levels or radionuclide scanning in euthyroid patients for malignancy assessment, as most thyroid cancers present with normal thyroid function 2
- Do not perform FNA on nodules <1 cm without high-risk features, as this leads to overdiagnosis and overtreatment of clinically insignificant papillary microcarcinomas 2
- Do not override a reassuring FNA when worrisome clinical findings persist, as false-negative results occur in up to 11-33% of cases 1
- Avoid palpation-guided FNA; ultrasound guidance is superior for accuracy, patient comfort, and cost-effectiveness 1